Western Blotting (WB), ELISA, Immunofluorescence (IF)
Purification
CLIP170 Antibody is affinity chromatography purified via peptide column.
Immunogène
CLIP170 antibody was raised against a 17 amino acid synthetic peptide from near the carboxy terminus of human CLIP170. The immunogen is located within amino acids 1340 - 1390 of CLIP170.
CLIP1
Reactivité: Humain, Souris, Rat
WB, ICC
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
CLIP170 antibody can be used for detection of CLIP170 by Western blot at 0.5 - 1 μ,g/mL. Antibody can also be used for immunoflourescence starting at 20 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in rat samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
CLIP170 Antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
CLIP170 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Antigène
CLIP1
(CAP-GLY Domain Containing Linker Protein 1 (CLIP1))
CLIP170 Antibody: CLIP170 was initially identified as a new type of intermediate filament associated protein that is highly expressed in Reed-Sternberg cells, the tumoral cells diagnostic for Hodgkin's disease. Later experiments showed that it is located at microtubule plus ends and is required for the binding of endocytic carrier vesicles. CLIP170 has also been suggested to act with LIS1, a protein implicated in brain development, to regulate dynein/dynactin binding microtubules. Other studies suggest that CLIP170 can influence the formation of lamellipodia and cell invasion by invasive breast cancer cells by regulating the release of kinesin and IQGAP1 from a complex of those proteins, CLIP170 and Rac1. At least two isoforms of CLIP170 are known to exist.